#EULAR24: J&J’s Sjögren’s disease drug shows promise in Phase 2, boosting...
Johnson & Johnson detailed positive data from a mid-stage trial in people with Sjögren’s disease that, according to some analysts, could be an encouraging signal for the FcRn inhibitor class that...
View ArticleUpdated: FDA places partial hold on BioNTech-MediLink ADC after multiple deaths
The FDA placed an early-stage BioNTech trial on partial clinical hold after researchers observed multiple deaths, the company said in an SEC filing Monday. Regulators told BioNTech partner MediLink...
View ArticleArgenx drops post-Covid syndrome program; Mirum picks a dose for bile duct...
Plus, news about Y-Biologics, Navigator Medicines, Spur Therapeutics, Disc Medicine and Mereo BioPharma: Argenx axes Covid-driven POTS program: The Dutch biotech’s efgartigimod did not meaningfully...
View ArticleJ&J cements footprint in Italy with €580M in investments over the next 5 years
Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, is earmarking €580 million ($622 million) in investments in Italy over the next five years. The company’s first step is to...
View ArticleClik here to view.
Amgen nabs new Blincyto approval for certain type of leukemia
The FDA on Friday gave its stamp of approval to Amgen’s Blincyto to treat both adults and children with the most common type of acute lymphoblastic leukemia, marking the third indication for the drug....
View ArticleJanssen ordered to pay $150M over false claims around HIV drugs
A jury found J&J’s Janssen liable for $150 million in damages in New Jersey federal court last week, ruling that the company owed $120 million for violating the False Claims Act and $30 million for...
View ArticleClik here to view.
Life sciences investor Decheng Capital targets $700M for fifth fund
After $900 million and $500-plus million fund closures last week from Foresite Capital and JP Morgan, respectively, another firm wants to enter the upper echelons of life sciences investing. Decheng...
View ArticleFDA approves endometrial cancer indications for Keytruda, Imfinzi
The FDA has granted two new endometrial cancer indications to rival immunotherapies: Merck’s Keytruda and AstraZeneca’s Imfinzi. On Monday, regulators approved Merck’s PD-1 blockbuster Keytruda in...
View ArticleGSK readies Blenrep's commercial re-launch in the US, and a push in second line
GSK is gearing up for the revival of multiple myeloma drug Blenrep, having hung onto the salesforce that was assembled when the drug first nabbed accelerated approval in 2020, only to be pulled after a...
View ArticleMerck's 21-valent pneumococcal vaccine for adults wins FDA approval
Merck’s 21-valent pneumococcal vaccine was approved by the FDA on Monday, bringing a new competitor to market for Pfizer’s 20-valent product. Merck’s vaccine, called Capvaxive, was specifically...
View ArticleClik here to view.
Philips works on tech to connect disparate healthcare and bio-tracking devices
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As more medical devices that measure biodata show up in the market, healthcare electronics giant Philips...
View ArticleAstraZeneca’s Truqap combo flops in Phase 3 triple-negative breast cancer trial
AstraZeneca’s Truqap failed to boost survival in a late-stage test in certain patients with triple-negative breast cancer, dealing a blow to the company’s efforts to expand the drug’s label. In the...
View ArticleMarea Therapeutics raises $190M in debut, targeting overlooked ANGPTL4 in...
A Third Rock Ventures-incubated startup called Marea Therapeutics debuted Tuesday with $190 million to advance a drug for a genetic target for cardiometabolic diseases. The San Francisco-based biotech...
View ArticleHow two academic chemists turned San Diego startup Iambic into an AI force
SAN DIEGO — In the first months of their startup’s existence, Tom Miller and Fred Manby sent an invitation to the research chemist and drug industry blogger Derek Lowe to join their scientific advisory...
View ArticleClik here to view.
As it deepens immunology bets, Sanofi inks small molecule pact with Belharra
Belharra Therapeutics is riding the waves of Sanofi’s bid to become an “immunology powerhouse.” The California biotech — whose name derives from a famous surf break in France’s Basque region — will get...
View ArticleClik here to view.
Roche strikes neuro-focused partnership with RNA exon editing startup Ascidian
Roche has tapped a small Boston startup for access to a sweeping form of RNA editing that replaces large swathes of errant genetic code. Broadly known as RNA writing, scientists have said the...
View ArticleClik here to view.
Hikma to take over several assets from Xellia, including a US manufacturing site
Generic drug company Hikma is bolstering its portfolio by acquiring parts of Xellia Pharmaceuticals’ finished dosage form business in the US. This includes Hikma taking on a manufacturing site as well...
View ArticleA new obesity biotech; UroGen aims to raise $107M
Plus, news about Otsuka, Ionis, Ability Biologics, Santhera, Mustang Bio and Vaxart: New biotech joins obesity race: Supercede Therapeutics raised an undisclosed seed round from an unnamed investor to...
View ArticleClik here to view.
Day One enters ADC field, going after a target that once attracted AbbVie and...
Shortly after securing its first FDA approval and bagging $108 million from a priority review voucher sale, Day One Biopharmaceuticals is entering the hottest pocket of oncology drug development —...
View ArticleClik here to view.
After two patient deaths from presumed sepsis, FDA puts partial hold on...
The FDA put three clinical studies of Zentalis’ WEE1 inhibitor on partial hold following two patient deaths likely from sepsis in one study earlier this year. The two patients were part of the Phase 2...
View Article